Cerus Endovascular Ltd. today announced that it has received CE Mark approval for the commercial sale of its Contour Neurovascular System™ for the treatment of intra-cranial aneurysms (IAs) across the ...
FREMONT, Calif. and OXFORD, United Kingdom, April 21, 2021 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, today announced that the U.S. Food and ...
FREMONT, Calif. and OXFORD, United Kingdom , Dec. 17, 2020 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial stage medical device company, today announced the first ever ...
Commercial Sales Across European Union Expected to Begin in Second Quarter of 2020 "As our clinical data experience grows, and more physicians use the System, results continue to be compelling – ...
The U.S. FDA has granted breakthrough device designation to Cerus Endovascular Ltd. for its Contour neurovascular system for the treatment of intracranial aneurysms. The company is targeting the ...
FREMONT, Calif. and OXFORD, England, Sept. 7, 2017 /PRNewswire/ -- Cerus Endovascular Ltd., a privately-held, commercial-stage medical device company engaged in the design and development of highly ...
FREMONT, Calif. and OXFORD, England, March 23, 2022 /PRNewswire/ -- Cerus Endovascular Ltd., a privately held, commercial-stage medical device company, announced today that it has received U.S. Food ...
FREMONT, Calif. and OXFORD, United Kingdom, July 6, 2017 /PRNewswire/ -- Cerus Endovascular Ltd. today announced that it has received CE Mark approval for the commercial sale of its Contour ...
The U.S. FDA has granted breakthrough device designation to Cerus Endovascular Ltd. for its Contour neurovascular system for the treatment of intracranial aneurysms. The company is targeting the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback